Table 2 Comparison of patient, tumour, and treatment characteristics among subgroups of Asian women (n=4770) aged 18–39 years with breast cancer
Characteristic | Filipino ( n =1040) | Japanese ( n =602) | Chinese ( n =995) | Hawaiian/Pacific Islander ( n =540) | Korean ( n =339) | Asian Indian/Pakistani ( n =410) | Vietnamese ( n =307) | Other ( n =537) | P- value |
|---|---|---|---|---|---|---|---|---|---|
Disease stage | <0.0001 | ||||||||
Localised | 529 (51.9) | 352 (59.3) | 536 (55.1) | 257 (49.0) | 172 (51.7) | 176 (43.7) | 174 (57.2) | 281 (53.2) | |
Regional | 432 (42.3) | 223 (37.5) | 397 (40.8) | 230 (43.8) | 150 (45.0) | 206 (51.1) | 117 (38.5) | 223 (42.2) | |
Distant | 59 (5.8) | 19 (3.2) | 40 (4.1) | 38 (7.2) | 11 (3.3) | 21 (5.2) | 13 (3.3) | 24 (4.6) | |
Unknown | 20 | 8 | 22 | 15 | 6 | 7 | 3 | 9 | |
Age at diagnosis (years) | 0.06a | ||||||||
Mean (median) | 35.1 (36) | 35.2 (36) | 35.1 (36) | 34.7 (36) | 35.3 (36) | 34.4 (35) | 34.9 (36) | 35.2 (36) | |
<35 | 368 (35.4) | 203 (33.7) | 349 (35.1) | 209 (38.7) | 114 (33.6) | 174 (42.4) | 115 (37.5) | 184 (34.6) | 0.08 |
⩾35 | 672 (64.6) | 399 (66.3) | 646 (64.9) | 331 (61.3) | 225 (66.4) | 236 (57.6) | 192 (62.5) | 351 (65.4) | |
Surgery | 0.001 | ||||||||
No primary surgery | 37 (3.6) | 12 (2.0) | 33 (3.3) | 25 (4.7) | 11 (3.2) | 24 (5.9) | 7 (2.3) | 26 (4.8) | |
SM | 357 (34.5) | 227 (38.2) | 370 (37.5) | 183 (34.3) | 151 (44.7) | 173 (42.4) | 119 (38.8) | 195 (36.8) | |
TM | 639 (61.9) | 355 (59.8) | 584 (59.2) | 325 (61.0) | 176 (52.1) | 211 (51.7) | 181 (58.9) | 309 (58.3) | |
Unknown | 7 | 8 | 8 | 7 | 1 | 2 | 0 | 1 | |
Tumour grade | 0.002b | ||||||||
I | 67 (8.1) | 53 (12.3) | 68 (8.7) | 37 (8.9) | 32 (11.1) | 21 (5.6) | 18 (6.5) | 40 (9.0) | |
II | 286 (34.7) | 156 (36.2) | 288 (37.0) | 138 (33.3) | 86 (30.0) | 112 (30.2) | 102 (36.8) | 170 (38.3) | |
III | 442 (53.6) | 200 (46.4) | 406 (52.2) | 225 (54.2) | 152 (53.0) | 227 (61.2) | 145 (52.4) | 221 (49.8) | |
IV | 29 (3.5) | 22 (5.1) | 16 (2.1) | 15 (3.6) | 17 (5.9) | 11 (3.0) | 12 (4.3) | 13 (2.9) | |
Unknown | 216 | 171 | 217 | 125 | 52 | 21 | 18 | 40 | |
Histology | 0.03 | ||||||||
IDC | 817 (78.6) | 498 (82.7) | 785 (78.9) | 427 (79.1) | 273 (80.5) | 324 (79.0) | 242 (78.8) | 427 (79.5) | |
ILC | 21 (2.0) | 10 (1.7) | 19 (1.9) | 9 (1.7) | 6 (1.8) | 14 (3.4) | 1 (0.3) | 17 (3.2) | |
IDC and ILC | 41 (3.9) | 17 (2.8) | 43 (4.3) | 20 (3.7) | 20 (5.9) | 24 (5.9) | 17 (5.5) | 12 (2.2) | |
Other | 161 (15.5) | 77 (12.8) | 148 (14.9) | 84 (15.5) | 40 (11.8) | 48 (11.7) | 47 (15.3) | 81 (15.1) | |
Oestrogen receptor status | 0.08b | ||||||||
Positive | 513 (68.4) | 247 (68.0) | 510 (70.7) | 266 (68.6) | 183 (66.1) | 216 (61.0) | 175 (68.4) | 286 (71.1) | |
Negative | 237 (31.6) | 116 (32.0) | 211 (29.3) | 122 (31.4) | 94 (33.9) | 138 (39.0) | 81 (31.6) | 116 (28.9) | |
Unknown | 290 | 239 | 274 | 152 | 62 | 56 | 51 | 135 | |
Progesterone receptor status | 0.1b | ||||||||
Positive | 465 (63.7) | 232 (64.4) | 478 (67.0) | 251 (65.9) | 171 (63.1) | 199 (56.9) | 160 (62.7) | 259 (65.6) | |
Negative | 265 (36.3) | 128 (35.6) | 236 (33.0) | 130 (34.1) | 100 (36.9) | 151 (43.1) | 95 (37.3) | 136 (34.4) | |
Unknown | 310 | 242 | 281 | 159 | 68 | 60 | 52 | 142 | |
Adjuvant radiation therapy | <0.0001 | ||||||||
No | 605 (58.2) | 337 (56.0) | 567 (57.0) | 323 (59.8) | 186 (54.9) | 190 (46.3) | 176 (57.3) | 338 (62.9) | |
Yes | 435 (41.8) | 265 (44.0) | 428 (43.0) | 217 (40.2) | 153 (45.1) | 220 (53.7) | 131 (42.7) | 199 (37.1) | |
Adjuvant radiation therapy after SM | 0.8 | ||||||||
No | 106 (29.7) | 65 (28.6) | 101 (27.3) | 60 (32.8) | 47 (31.1) | 50 (28.9) | 37 (31.1) | 66 (33.8) | |
Yes | 251 (70.3) | 162 (71.4) | 269 (72.7) | 123 (67.2) | 104 (68.9) | 123 (71.1) | 82 (68.9) | 129 (66.2) | |
Adjuvant radiation therapy after TM | <0.0001 | ||||||||
No | 457 (71.5) | 252 (71.0) | 426 (73.0) | 233 (71.7) | 128 (72.7) | 116 (55.0) | 133 (73.5) | 239 (77.3) | |
Yes | 182 (28.5) | 103 (29.0) | 158 (27.0) | 92 (28.3) | 48 (27.3) | 95 (45.0) | 48 (26.5) | 70 (22.7) |
